Zaphyr Pharmaceuticals is pleased to announce that it has entered into an exclusive supply and distribution agreement with Swiss company Gene Signal, relating to their product GS-101 (aganirsen) eye-drops, under development for the treatment of several ophthalmological conditions.
The lead indication is for the treatment of corneal neovascularization, where one phase III trial has been completed, demonstrating good safety and efficacy. A second confirmatory trial is on-going.
Under this agreement Zaphyr Pharmaceuticals gets the exclusive rights to GS-101 in GCC, Iraq, Iran, Egypt, Lebanon, Tunisia, Algeria and Morocco, and will be responsible for the distribution, provision and sale of the product in that territory.
GS-101 is a very exciting product under development for a number of indications with high unmet medical needs and provides a new treatment option for patients suffering from abnormal growth of blood vessels in the eye, a common problem within ophthalmology.
About Gene Signal
Gene Signal International SA is a Swiss-based biotechnology company pioneering the development of innovative therapies for angiogenesis-based diseases. Its product candidates are a new class of oligonucleotides, proteins and monoclonal antibodies, which are derived from genes that are exclusively involved in the angiogenesis process. At least four official candidates are in development for eleven indications in ophthalmology, dermatology, vascular disorders and cancer. The company was founded in 2000, is privately owned, and is led by a team of highly qualified scientific and commercial talents. Its headquarters are in Lausanne (EPFL Swiss Federal Institute of Technology), Switzerland, with research programs based in France (Bioparc Genopole, Evry) and product development in Canada (Montreal). For more information, please visit: www.genesignal.com